Legend Biotech Corp
9LB
Company Profile
Business description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Contact
2101 Cottontail Lane
SomersetNJ08873
USAT: +1 737 317-5050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,700
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,785.60 | 12.60 | 0.14% |
| CAC 40 | 7,665.91 | 25.64 | -0.33% |
| DAX 40 | 23,909.61 | 123.61 | -0.51% |
| Dow JONES (US) | 44,094.77 | 275.50 | 0.63% |
| FTSE 100 | 8,760.96 | 37.95 | -0.43% |
| HKSE | 24,072.28 | 211.87 | -0.87% |
| NASDAQ | 20,369.73 | 96.27 | 0.47% |
| Nikkei 225 | 40,059.56 | 427.83 | -1.06% |
| NZX 50 Index | 12,663.10 | 60.28 | 0.48% |
| S&P 500 | 6,204.95 | 31.88 | 0.52% |
| S&P/ASX 200 | 8,558.00 | 15.70 | 0.18% |
| SSE Composite Index | 3,444.43 | 20.20 | 0.59% |